ULOCUPLUMAB: A POTENTIAL TREATMENT FOR ALPHA-GAL ALLERGY

Ulocuplumab represents a major breakthrough in the management of Alpha-Gal reaction, a expanding condition prompted by tick bites. This novel drug works by inhibiting the Alpha-Gal allergen before it interacts with the immune response, possibly reducing allergic reactions. Initial research have i